ArticleBMC public health2025
Non-COVID-19 mortality among older people or with chronic conditions during year 2020 in France: a nationwide cohort study.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Perceptions of care quality and human rights in Italian outpatient facilities during and after the pandemic.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMeasures to contain the COVID-19 pandemic led to healthcare services underutilisation during year 2020, with potential harmful consequences for people with specific needs. Our objective was to assess non-COVID-19 mortality (referred to as "non-covid") during year 2020 in a population of older people or with chronic conditions in France.
methodsA nationally representative sample of adults aged 70 or more or with chronic conditions was followed from the beginning of the first lockdown to 31/12/2020. We used causes of death data to measure non-covid mortality during the entire study period and three additional periods: March 17 to May 10 (first lockdown), May 11 to October 29 (between the two lockdowns), October 30 to December 14 (second lockdown). We computed Standardized Mortality Ratios (SMRs) for the entire study population and for groups of interest defined upon age, sex, socioeconomic position, prevalent conditions and region of residence, using a 2016-2017 population as reference.
resultsOverall, non-covid deaths among the 1,594,222 individuals included (mean age 68·4 years, 54% women) were 2% lower than expected (SMR 0·98 [0·97 - 0·99]). Non-covid mortality was lower only during first lockdown for men (SMR 0·94 [0·91 - 0·98]) and during second lockdown for women (SMR 0·93 [0·90 - 0·96]). Excess non-covid mortality was observed for people with dementia (SMR 1·08 [1·03 - 1·14]), Ile-de-France residents (SMR 1·07 [1·01-1·15]) and Occitanie residents (SMR 1·14 [1·06 - 1·23]) during the first lockdown; people with end-stage renal disease (SMR 1·15 [1·03 - 1·28]) and Corse residents (SMR 1·34 [1·13 - 1·60]) between lockdowns; residents of the most deprived areas (SMR 1·05 [1·00-1·11] during second lockdown. Analyses stratified by region of residence confirmed the results for people with dementia and also revealed excess non-covid mortality for people with diabetes and cardiovascular diseases.
conclusionsNon-covid mortality was lower than expected during year 2020 among older people or with chronic conditions in France. Analyses during defined periods and analyses stratified by regions found significant excess non-covid mortality among specific groups of interest. Extending follow-up to years 2021 and 2022 is necessary to confirm non-covid excess mortality and assess the potential effect of healthcare underutilisation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.